natgillin/translations-raw huggingface dataset:
- metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.
kot trojno peroralno zdravljenje v kombinaciji z metforminom in sulfonilsečnino pri odraslih bolnikih (predvsem bolnikih s prekomerno telesno maso) z nezadostnim nadzorom glikemije kljub dvojnemu peroralnemu zdravljenju.
Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone.
Poročali so, da sočasno dajanje pioglitazona z rifampicinom (induktor citokroma P450 2C8) povzroči 54 % zmanjšanje AUC pioglitazona.
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking pioglitazone.
Rak mehurja se lahko pojavi občasno (pojavijo se lahko pri največ 1 od 10 bolnikov) pri bolnikih, ki jemljejo pioglitazon.
Cardiac disorders heart failure3
Srčne bolezni srčno popuščanje3
How to take Pioglitazone Teva
Kako jemati zdravilo Pioglitazon Teva
Epidemiological studies have also suggested a small increased risk of bladder cancer in diabetic patients treated with pioglitazone, although not all studies identified a statistically significant increased risk.
zdravljenih s pioglitazonom, čeprav pri vseh študijah povečanje tveganja ni bilo statistično signifikantno.
This leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano mesec LLLL Drugi viri informacij
Respiratory, thoracic and mediastinal disorders dyspnoea common
Bolezni dihal, prsnega koša in mediastinalnega prostora dispneja
There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure.
S trga so poročali o primerih srčnega popuščanja, ko so pioglitazon uporabljali v kombinaciji z insulinom ali pri bolnikih s srčnim popuščanjem v anamnezi.
Take Pioglitazone Teva daily as prescribed.
Če ste pozabili vzeti zdravilo Pioglitazon Teva Zdravilo Pioglitazon Teva jemljite vsak dan, kakor vam je predpisano.
If you experience this side effect, talk to your doctor as soon as possible.
Če ste opazili ta neželeni učinek, se posvetujte s svojim zdravnikom kakor hitro mogoče.
Hypoglycaemia may occur in combination with sulphonylureas or insulin.
V kombinaciji s sulfonilsečninami ali insulinom se lahko pojavi hipoglikemija.
Pioglitazone Teva should be used every day to work properly.
Za pravilno delovanje je potrebno zdravilo Pioglitazon Teva jemanti vsak dan.
However, certain medicines are especially likely to affect the amount of sugar in your blood: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections) Tell your doctor or pharmacist if you are taking any of these.
- gemfibrozil (uporablja se za zniževanje holesterola) - rifampicin (uporablja se za zdravljenje tuberkuloze in drugih okužb)
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDLcholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels.
V večini kliničnih preskušanj so opažali znižane skupne plazemske koncentracije trigliceridov in prostih maščobnih kislin ter povišane ravni HDL holesterola v primerjavi s placebom, z majhnimi,
Allergic reactions have been reported (frequency cannot be estimated from the available data) in patients taking pioglitazone.
Pri bolnikih, ki jemljejo zdravilo pioglitazon, so poročali o alergijskih reakcijah (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked.
Če bolnik razvije simptome, ki kažejo na moteno delovanje jeter, kar lahko vključuje nepojasnjeno slabost, bruhanje,
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to medical prescription.
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z
Metabolism and nutrition disorders hypo-glycaemia uncommon very common
Presnovne in prehranske motnje hipo-glikemija občasni zelo pogosti povečan apetit občasni
A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%).
Opazili so višjo stopnjo zlomov pri ženskah, ki so jemale pioglitazon (2,6 %) v primerjavi s primerjalnim zdravilom (1,7 %).
No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%).
Pri moških, zdravljenih s pioglitazonom, niso opazili povečane stopnje zlomov (1,3 %) v primerjavi s primerjalnim zdravilom (1,5 %).
Your weight should be checked at regular intervals; if your weight increases, inform your doctor.
Če se vam telesna masa znatno poveča, o tem obvestite svojega zdravnika.
The other side effects that have been experienced by some patients taking pioglitazone are:
Pri nekaterih bolnikih, ki so jemali pioglitazon, so se pojavili drugi neželeni učinki:
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone.
Pri tiazolidindionih, vključno s pioglitazonom, so v postmarketinških poročilih poročali o novonastalih ali poslabšanjih diabetičnega makularnega edema z zmanjšanjem vidne ostrine.
It is an anti-diabetic medicine used to treat type 2 (noninsulin dependent) diabetes mellitus in adults, when metformin is not suitable or has failed to work adequately.
Je antidiabetično zdravilo za zdravljenje sladkorne bolezni tipa 2 (od insulina neodvisne sladkorne bolezni) pri odraslih.
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years.
V skupni analizi neželenih učinkov zlomov kosti iz randomiziranih, nadzorovanih, dvojno slepih kliničnih preskušanj pri več kot 8100 s pioglitazonom in 7400 s primerjalnim zdravilom zdravljenimi bolniki, ki so se zdravili do 3,5 let, so opazili povečano incidenco zlomov kosti pri ženskah.
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin common appetite increased uncommon
Kombinacija z metforminom s sulfonil sečnino z metforminom in sulfonil sečnino z inzulinom sistema in vezivnega tkiva zlomi kosti4
Weight gain
- povečan apetit
Also, if you already have blurred vision and the symptom gets worse, talk to your doctor as soon as possible.
Prav tako se kakor hitro mogoče posvetujte s svojim zdravnikom, če ste imeli zamegljen vid že prej, pa se vam je stanje poslabšalo.
Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin).
Pri uporabi pioglitazona in sočasnim dajanjem z zaviralci (npr. gemfibrozil) ali induktorji (npr. rifampicin) citokroma P450 2C8 je potrebna previdnost.
Pioglitazone should be discontinued if any deterioration in cardiac status occurs.
Če se pojavi kakršnokoli poslabšanje srčnega statusa, je treba zdravljenje s pioglitazonom ukiniti.
Teл.
ČET
No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%).
Pri moških, zdravljenih s pioglitazonom, niso opazili povečane stopnje zlomov (1,7 %) v primerjavi s primerjalnim zdravilom (2,1 %).
The formation and presence of urinary calculi with subsequent irritation and hyperplasia was postulated as the mechanistic basis for the observed tumourigenic response in the male rat.
predstavljalo mehansko osnovo opaženega tumorogenega odgovora pri samcih podgan.
Nervous system disorders hypo-aesthesia common common common common common headache common uncommon dizziness common insomnia uncommon uncommon uncommon uncommon uncommon
Bolezni živčevja hipestezija glavobol občasni omotica nespečnost občasni občasni občasni občasni občasni
A clinical trial of pioglitazone vs. gliclazide as monotherapy was extended to two years in order to assess time to treatment failure (defined as appearance of HbA1c ≥ 8.0% after the first six months of therapy).
Za oceno časa do neuspeha zdravljenja (definirano kot pojav HbA1c ≥ 8,0 % po prvih šest mesecih zdravljenja) so klinično preskušanje pioglitazona v primerjavi z gliklazidom kot monoterapiji podaljšali na dve leti.
Foetal growth restriction was apparent in animal studies with pioglitazone.
V študijah s pioglitazonom na živalih so opažali zastoj v rasti plodu.
common (may affect up to 1 in 10 people) - headache - dizziness - joint pain - impotence - back pain - shortness of breath - small reduction in red blood cell count - flatulence uncommon (may affect up to 1 in 100 people) - sugar in urine, proteins in urine - increase in enzymes - spinning sensation (vertigo) - sweating - tiredness - increased appetite
- vetroviobčasni (pojavijo se lahko pri največ 1 od 100 bolnikov) - sladkor v urinu, beljakovine v urinu - povišanje vrednosti encimov
- Pioglitazone Teva 30 mg tablets are white to off white, round, convex with the number ‘30' on one side and ‘TEVA' on the other side.
- Tablete zdravila Pioglitazon Teva 30 mg so bele do umazano bele barve, okrogle, izbočene, z oznako »30« na eni strani in »TEVA« na drugi strani.
Neoplasms benign, malignant and unspecified (including cysts and polyps)
Benigne, maligne in neopredeljene novotvorbe
Blurred vision due to swelling (or fluid) at the back of the eye (frequency cannot be estimated from the available data) has also been reported in patients taking pioglitazone.
Pacienti, ki so jemali pioglitazon, so poročali tudi o zamegljenem vidu zaradi otekanja (ali tekočine) očesnega ozadja (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Renal and urinary disorders haematuria common glycosuria uncommon proteinuria uncommon
Bolezni sečil hematurija glikozurija občasni proteinurija občasni
Broken bones have been reported commonly (may affect up to 1 in 10 people) in female patients taking pioglitazone and have also been reported in male patients (frequency cannot be estimated from the available data) taking pioglitazone.
O zlomih so poročali tudi pri bolnikih, ki so se zdravili s pioglitazonom (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
The observed excess risk of fractures for women in this dataset on pioglitazone is therefore 0.8 fractures per 100 patient years of use.
Opazovano povečano tveganje za zlom pri ženskah v tej skupini podatkov na pioglitazonu je torej
- Pioglitazone Teva 45 mg tablets are white to off white, round, convex with the number ‘45' on one side and ‘TEVA' on the other side.
- Tablete zdravila Pioglitazon Teva 45 mg so bele do umazano bele barve, okrogle, izbočene, z oznako »45« na eni strani in »TEVA« na drugi strani.
Teva UK Ltd Brampton Road, Hampden Park, Eastbourne,
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG Velika Britanija
Pioglitazone Teva 30 mg tablets Each tablet contains 30 mg of pioglitazone (as hydrochloride).
Pioglitazon Teva 30 mg tablete Ena tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida).
- Pioglitazone Teva 15 mg tablets are white to off white, round, convex with the number ‘15' on one side and ‘TEVA' on the other side.
- Tablete zdravila Pioglitazon Teva 15 mg so bele do umazano bele barve, okrogle, izbočene, z oznako »15« na eni strani in »TEVA« na drugi strani.
Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5).
(induktor citokroma P450 2C8) poviša oziroma zniža plazemsko koncentracijo pioglitazona (glejte poglavje 4.5).
If you stop using Pioglitazone Teva, your blood sugar may go up.
Če ste prenehali jemati zdravilo Pioglitazon Teva, se vam lahko raven krvnega sladkorja zviša, zato se posvetujte z zdravnikom, preden prenehate s tem zdravljenjem.
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea as triple oral therapy in combination with
s sulfonilsečnino, samo pri bolniki, ki kažejo intolerance na metformin ali pri katerih je metformin kontraindiciran, z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku monoterapije s sulfonilsečnino.
Pioglitazone Teva 45 mg tablets Each tablet contains 45 mg of pioglitazone (as hydrochloride).
Pioglitazon Teva 45 mg tablete Ena tableta vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida).
The tablets are white to off-white, round, convex and debossed with the number ‘45' on one side and ‘TEVA' on the other side.
Tablete so bele do umazano bele barve, okrogle, izbočene, z oznako »45« na eni strani in »TEVA« na drugi strani.
The tablets are white to off-white, round, convex and debossed with the number ‘30' on one side and ‘TEVA' on the other side.
Tablete so bele do umazano bele barve, okrogle, izbočene, z oznako »30« na eni strani in »TEVA« na drugi strani.
Pioglitazone Teva 15 mg tablets Each tablet contains 15 mg of pioglitazone (as hydrochloride).
Pioglitazon Teva 15 mg tablete Ena tableta vsebuje 15 mg pioglitazona (v obliki pioglitazonijevega klorida).
Pioglitazone Teva 30 mg tablets Pioglitazone
Pioglitazone Teva 30 mg tablete pioglitazon
Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone.
koronarnih revaskularizacij in revaskularizacij nog, rezultati kažejo, da ni dolgoročnih kardiovaskularnih skrbi glede uporabe pioglitazona.
Each tablet contains 45 mg pioglitazone (as hydrochloride).
Ena tableta vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida).
not known (frequency cannot be estimated from the available data) - increase in liver enzymes - allergic reactions
- težave s spanjem (nespečnost) neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)
Pioglitazone Teva 15 mg tablets Pioglitazone
Pioglitazone Teva 15 mg tablete pioglitazon
Carmellose calcium Hydroxypropylcellulose Magnesium stearate
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi manitol kalcijev karmelozat hidroksipropilceluloza magnezijev stearat
Each tablet contains 30 mg pioglitazone (as hydrochloride).
Ena tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida).
The tablets are white to off-white, round, convex and debossed with the number ‘15' on one side and ‘TEVA' on the other side.
Tablete so bele do umazano bele barve, okrogle, izbočene, z oznako »15« na eni strani in »TEVA« na drugi strani.
Each tablet contains 15 mg pioglitazone (as hydrochloride).
Ena tableta vsebuje 15 mg pioglitazona (v obliki pioglitazonijevega klorida).
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency.
Neželeni učinki, o katerih so poročali večkrat (> 0,5 %) kot pri placebu in več kot enkrat pri bolnikih,
Pioglitazone Teva contains pioglitazone.
Zdravilo Pioglitazon Teva vsebuje pioglitazon.
Each Pioglitazone Teva 30 mg tablet contains 30 mg of pioglitazone (as hydrochloride).
Ena 30-miligramska tableta Pioglitazon Teva vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida).
common (may affect up to 1 in 10 people) - respiratory infection - abnormal vision - weight gain - numbness uncommon (may affect up to 1 in 100 people) - inflammation of the sinuses (sinusitis) - difficulty sleeping (insomnia)
pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov) - okužba dihal - motnje vida
common common common common common arthralgia common common common back pain common
rak sečnega mehurja občasni občasni občasni občasni občasni
Pioglitazone Teva may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control of blood sugar.
Zdravilo Pioglitazon Teva lahko uporabljamo samo ali skupaj z metforminom in / ali sulfonilsečnino, ki je tudi peroralno antidiabetično zdravilo.
Each Pioglitazone Teva 45 mg tablet contains 45 mg of pioglitazone (as hydrochloride).
Ena 45-miligramska tableta Pioglitazon Teva vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida).
Each Pioglitazone Teva 15 mg tablet contains 15 mg of pioglitazone (as hydrochloride).
Ena 15-miligramska tableta Pioglitazon Teva vsebuje 15 mg pioglitazona (v obliki pioglitazonijevega klorida).
Elimination
Odmerjanje
Gastrointestinal disorders flatulence uncommon common
Bolezni prebavil flatulenca občasni
Posology
ZDRAVILA
It is especially important to mention these:
Posebno pomembno je omeniti naslednje:
• At the request of the European Medicines Agency;
• Na zahtevo Evropske agencije za zdravila;
Date of first authorisation: 22 August 2016
Datum prve odobritve: 22 avgust 2016
No deaths were reported.
O smrtnih primerih niso poročali.
** Based on historical comparison.
**Na osnovi predhodnih primerjav.
(See sections 4.2 and 4.4.)
(glejte poglavji 4.2 in 4.4.)
15 to less than 35
15 do manj kot 35
The clinical relevance of these non-clinical data is unknown.
Klinični pomen teh nekliničnih podatkov ni znan.
The mechanism of this decrease is unknown.
Mehanizem za to zmanjšanje ni znan.
Confidence interval.
Interval zaupanja.
Biosciences, South San Francisco, California, USA)
Biosciences, South San Francisco, Kalifornija, ZDA)
These could be symptoms of a serious heart problem.
To so lahko simptomi resnih težav s srcem.
Wait and take the next dose at its regular time.
Počakajte in vzemite naslednji odmerek ob običajnem času.
It is normally used in combination with other anti-HIV medicines.
Običajno se predpisuje v kombinaciji z drugimi zdravili proti HIV.
In some patients additional factor VIII was given.
Nekateri bolniki so prejeli dodaten faktor VIII.
During the second and third trimesters of pregnancy
Drugo in tretje trimesečje nosečnosti
Paediatric patients (less than 3 months of age)
Pediatrični bolniki (mlajši od 3 mesecev)
The studies presented in Table 2 were conducted in healthy subjects unless otherwise noted.
Študije, navedene v preglednici 2, so bile izvedene pri zdravih osebah, če ni drugače navedeno.
The same recommendations for drug drug interactions would apply except:
Upoštevati je treba enaka priporočila za medsebojno delovanje med zdravili, razen:
Food effect
Učinek hrane
Table 5: Efficacy Outcomes in Study 138
Preglednica 5: Izidi učinkovitosti v Študiji 138
(responder/evaluable)
(bolniki z odzivom/ovrednoteno)
Didanosine (with food)
didanozin (skupaj s hrano)
In the prepartum period, additional monitoring should be considered.
V predporodnem obdobju je potrebno dodatno nadziranje.
An alternate reliable method of contraception is recommended.
Priporočljiva je uporaba druge zanesljive metode kontracepcije.
Difference estimate e
Ocenjena razlika e
It is important to note that at time of the 96-week analysis, 48 % of patients overall remained on study.
Omeniti je treba, da je bilo v študiji v času analize po 96 tednih v celoti še 48% bolnikov.
If it is almost time for your next dose, do not take the missed dose.
Če je že skoraj čas za naslednji odmerek, ne vzemite pozabljenega odmerka.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Zahteve za predložitev redno posodobljenih poročil o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in vseh nadaljnjih posodobitev, objavljenih na evropskem spletnem portalu o zdravilih.
A causal relationship has been suggested, although the mechanism of action has not been elucidated.
Domnevamo, da gre za vzročno povezavo, vendar pa mehanizem delovanja ni pojasnjen.
Number of patients evaluable.
Število ovrednotenih bolnikov.
Without tenofovir
Brez tenofovirja
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
Consistent results were obtained with the last observation carried forward method of analysis (time-averaged difference of 0.11, 97.5% confidence interval [-0.15, 0.36]).
Konsistentni rezultati so bili doseženi z analizo po metodi prenosa zadnjega opažanja naprej (časovno povprečna razlika 0,11 pri 97,5 % intervalu zaupanja [-0,15, 0,36]).
• undetectable viral load during the last 6 months under current regimen
• nedokazljivo virusno breme v zadnjih 6 mesecih pri trenutnem režimu zdravljenja,
Caution should be exercised.
Potrebna je previdnost.
Your doctor will test for these changes.
Zdravnik bo opravil presikave za omenjene spremembe.
Do not take a double dose to make up for a forgotten dose.
Ne vzemite dvojnega odmerka, da bi nadomestili pozabljeni odmerek.
Tell your doctor if you notice anything unusual about your health.
Povejte zdravniku, če ste opazili kar koli neobičajnega.
Single doses up to 1,200 mg have been taken by healthy volunteers without symptomatic untoward effects.
Pri zdravih prostovoljcih posamični odmerki do 1.200 mg niso povzročili simptomatskih neželenih učinkov.
No differences in frequency of bilirubin elevations were observed between these patients and those without viral hepatitis.
Razlik v pogostnosti zvišanja bilirubina med temi bolniki in tistimi brez virusnega hepatitisa niso opažali.
100 mg at least 35
100 mg najmanj 35
Analyses of data through 96 weeks of treatment demonstrated durability of antiviral activity (Table 5).
Analize podatkov po 96 tednih zdravljenja kažejo trajnost protivirusne aktivnosti (preglednica 5).
• if you are allergic to atazanavir or any of the other ingredients of this medicine (listed in section 6)
• če ste alergični na atazanavir ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Do not use this medicine after the expiry date which is stated on the label, carton or blister.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki, škatli ali pretisnem omotu.
• hypersensitivity (allergic reaction)
• preobčutljivost (alergijska reakcija);
Withdrawal of ritonavir only under restrictive conditions
Odtegnitev ritonavirja le v omejenih pogojih
Thirty-two percent of patients in the study had a viral strain with fewer than two NRTI substitutions.
Dvaintrideset odstotkov bolnikov v študiji je imelo virusni sev z manj kot dvema substitucijama za NRTI.
Such changes may in part be linked to the disease control and life style.
Povišane je lahko deloma povezano z nadzorovanjem bolezni in življenjskim slogom.